<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178967</url>
  </required_header>
  <id_info>
    <org_study_id>17802</org_study_id>
    <secondary_id>2019-002933-12</secondary_id>
    <secondary_id>J2T-DM-KGAC</secondary_id>
    <secondary_id>DRM06-AD05</secondary_id>
    <nct_id>NCT04178967</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis</brief_title>
  <acronym>ADvocate2</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52&#xD;
      weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab&#xD;
      as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week&#xD;
      induction treatment period and a 36-week long-term maintenance treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Anticipated">June 13, 2022</completion_date>
  <primary_completion_date type="Actual">July 12, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, parallel group, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving EASI-75 (≥75% reduction in EASI score) from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving EASI-90 (≥90% reduction in EASI score) from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Pruritus Numerical Rating Scale (NRS) score from Baseline to Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Pruritus NRS score of ≥4-points at Baseline who achieve a ≥4-point reduction in Pruritus NRS score from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Pruritus NRS score of ≥5-points at Baseline who achieve a ≥4-point reduction in Pruritus NRS score from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in EASI score from Baseline to Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 16 in percent BSA</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving EASI-90 from Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving ≥4-point improvement in DLQI from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a DLQI total score of ≥4-point achieving ≥4-point improvement in DLQI from baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Sleep-loss score from Baseline to Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Sleep-loss score at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Sleep-loss score ≥2 points at Baseline who achieve a ≥2 points reduction from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Pruritus NRS score of ≥4 points at Baseline who achieve a ≥4-point reduction from Baseline to Week 1</measure>
    <time_frame>Baseline to Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Pruritus NRS score of ≥4 points at Baseline who achieve a ≥4-point reduction from Baseline to Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Pruritus NRS score of ≥4 points at Baseline who achieve a ≥4-point reduction from Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Pruritus NRS score of ≥5 points at Baseline who achieve a ≥4-point reduction from Baseline to Week 1</measure>
    <time_frame>Baseline to Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Pruritus NRS score of ≥5 points at Baseline who achieve a ≥4-point reduction from Baseline to Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a Pruritus NRS score of ≥5 points at Baseline who achieve a ≥4-point reduction from Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in SCORing Atopic Dermatitis (SCORAD) from Baseline to Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Average serum concentration of Lebrikizumab</measure>
    <time_frame>Baseline through Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants from those re-randomized having achieved EASI-75 at Week 16 who continue to exhibit EASI-75 at Week 52 (EASI-75 calculated relative to baseline EASI score)</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants from those re-randomized having achieved IGA 0 or 1 and a ≥2-point improvement from Baseline at Week 16 who continue to exhibit an IGA 0 or 1 and a ≥2-point improvement from Baseline at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants from those with a Pruritus NRS of ≥4-points at baseline re-randomized having achieved ≥4-point reduction from baseline at Week 16 who continue to exhibit ≥4-point reduction from baseline at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants from those with a Pruritus NRS of ≥5-points at baseline re-randomized having achieved ≥4-point reduction from baseline at Week 16 who continue to exhibit ≥4-point reduction from baseline at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in SCORAD (having achieved EASI-75 at Week 16) from baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Quality of Life-5 Dimensions (EQ5D) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Oriented Eczema Measure (POEM) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in PROMIS Depression at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Asthma Control Questionnaire (ACQ-5) score at Week 16 in participants who have self-reported comorbid asthma</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Induction Period (Baseline-Week 16):&#xD;
Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.&#xD;
Maintenance Period (Week 16-Week 52):&#xD;
Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Placebo arm receive two Placebo injections Q2W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lebrikizumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Period (Baseline-Week 16):&#xD;
Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 visits followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.&#xD;
Maintenance Period (Week 16-Week 52):&#xD;
Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q2W arm receive two lebrikizumab injections Q2W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lebrikizumab Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance Period (Week 16-Week 52):&#xD;
Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W, with one placebo injection 2 weeks after each lebikizumab injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escape Arm (Lebrikizumab Q2W)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance Period (Week 16-Week 52):&#xD;
Participants who require rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score &lt;50% of baseline), will be eligible for the Escape Arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lebrikizumab</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Escape Arm (Lebrikizumab Q2W)</arm_group_label>
    <arm_group_label>Lebrikizumab Q2W</arm_group_label>
    <arm_group_label>Lebrikizumab Q4W</arm_group_label>
    <other_name>LY3650150</other_name>
    <other_name>DRM06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>Lebrikizumab Q4W</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults and adolescents (≥12 years and ≥40 kg)&#xD;
&#xD;
          -  Chronic atopic dermatitis (according to American Academy of Dermatology Consensus&#xD;
             Criteria) that has been present for ≥1 year before the screening visit&#xD;
&#xD;
          -  Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit&#xD;
&#xD;
          -  Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit&#xD;
&#xD;
          -  ≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit&#xD;
&#xD;
          -  History of inadequate response to treatment with topical medications; or determination&#xD;
             that topical treatments are otherwise medically inadvisable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with dupilumab or tralokinumab&#xD;
&#xD;
          -  Treatment with topical corticosteroids, calcineurin inhibitors or phosphodiesterase-4&#xD;
             inhibitors such as crisaborole within 1 week prior to the baseline visit&#xD;
&#xD;
          -  Treatment with any of the following agents within 4 weeks prior to the baseline visit:&#xD;
&#xD;
               -  Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids,&#xD;
                  cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors,&#xD;
                  azathioprine, methotrexate, etc.)&#xD;
&#xD;
               -  Phototherapy and photochemotherapy (PUVA) for AD&#xD;
&#xD;
          -  Treatment with the following prior to the baseline visit:&#xD;
&#xD;
               -  An investigational drug within 8 weeks or within 5 half-lives (if known) of&#xD;
                  baseline, whichever is longer&#xD;
&#xD;
               -  Cell-depleting biologics, including to rituximab, within 6 months of baseline&#xD;
&#xD;
               -  Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever&#xD;
                  is longer&#xD;
&#xD;
          -  Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or&#xD;
             planned during the study&#xD;
&#xD;
          -  Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g.,&#xD;
             co-morbid severe uncontrolled asthma&#xD;
&#xD;
          -  Evidence of active acute or chronic hepatitis&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection or positive HIV serology&#xD;
&#xD;
          -  History of malignancy, including mycosis fungoides, within 5 years before the&#xD;
             screening visit, except completely treated in situ carcinoma of the cervix, completely&#xD;
             treated and resolved non-metastatic squamous or basal cell carcinoma of the skin&#xD;
&#xD;
          -  Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed&#xD;
             during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigate MD</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Arkansas Clinical Trials Center</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakersfield Dermatology and Skin Cancer Medical Group</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodward Centre</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA Universal Research Center, INC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luis Dermatology &amp; Laser Clinic</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Physiology Associates, Clinical Study Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916-9452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Direct Helpers Medical Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Community Research of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Pollens Clinical Research Centers, Inc</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Dermatology Clinical Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Dermatology, PA</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group, Inc.</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarkston Skin Research</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Skin Care Specialists</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology PC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Hills Dermatology Group</name>
      <address>
        <city>Kew Gardens</city>
        <state>New York</state>
        <zip>11415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Dermatology Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology and Skin Surgery Center</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermDOX</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peak Research LLC</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Laser Center of Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center, Inc</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovate Research, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah MidValley Dematology</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC Sveti Georgi</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Consultation Center 14</name>
      <address>
        <city>Sofia</city>
        <zip>1408</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandrovska University Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1432</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euro Derma clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical centre Alitera-Med EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simcoderm Medical &amp; Surgical Dermatology Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York Research Inc.</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M2M4J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Allergy Research Corp</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 6C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma-Study-Center Friedrichshafen GmbH</name>
      <address>
        <city>Friedrichshafen</city>
        <state>Baden-Württemberg</state>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Dr.Beate Schwarz</name>
      <address>
        <city>Langenau</city>
        <state>Baden-Württemberg</state>
        <zip>89129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis am Löwenmarkt</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>licca Fachklinik</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elbe Klinikum Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <state>Niedersachsen</state>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Osnabrück</name>
      <address>
        <city>Osnabrück</city>
        <state>Niedersachsen</state>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim</name>
      <address>
        <city>Bad Bentheim</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum im Jahrhunderthaus</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig - Universitätsklinikum</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIBAmed Studienzentrum GmbH &amp; Co. KG</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Michael Dietlen</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISA GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Ganzheitliche Dermatologie im Ärztehaus</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TFS Trial Form Support GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica De Enfermedades Cronicas y Procedimientos Especiales</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan Morelia</state>
        <zip>CP 58249</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma Norte del Bajío, S.C.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169078</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kk Women'S and Childrens Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Skin Centre NSC</name>
      <address>
        <city>Singapore</city>
        <zip>308205</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Niaosong Dist</city>
        <state>Kaohsiung City</state>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Institutional Review B</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University- Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution Kharkiv City Dermatoverenologic Dispensary N2</name>
      <address>
        <city>Kharkiv</city>
        <zip>61038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivne Regional Dermatology and Venereology Dispensary</name>
      <address>
        <city>Rivne</city>
        <zip>39028</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treatment-diagnostic center PE &quot;Asclepius&quot;</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Institution Zaporizhzhya Regional Dermatovenereology Clinical Hospital of Zaporizhzhya Regional Council</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>http://www.ADvocatestudies.com</url>
    <description>ADvocate Studies is to evaluate the safety and effectiveness of an injectable investigational medication for moderate to severe atopic dermatitis.</description>
  </link>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/AmPN68cQaViDZ8pT3j6hD</url>
    <description>Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <keyword>Dermatitis</keyword>
  <keyword>Dermatitis, Atopic</keyword>
  <keyword>Skin Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

